• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Isoquinolines are disclosed of the formula (I) <IMAGE> (I) wherein R independently represents hydrogen, hydroxyl or alkoxy having 1 to 4 carbon atoms, R1 is hydrogen, alkyl having 1 to 4 carbon atoms and optionally substituted with phenyl, phenyl optionally substituted with one or more halogen or alkoxy group, cyano or carbomoyl, R2 is phenyl optionally substituted with one or more halogen, alkoxy or carboxyl, or a group of the general formula A <IMAGE> wherein R3 is hydrogen, a straight or branched chained alkyl having 1 to 4 carbon atoms or phenyl, m and n independently represent 0, 1 or 2, with the proviso that m+n is at least 1, R4 is hydrogen, phenyl, hydroxyl, acyloxy, carboxyl, alkoxycarbonyl having 1 to 6 carbon atoms, carbamoyl, carbazoyl or dialkylamino containing 1 to 6 carbon atoms in the alkyl moiety, or R2 is a straight or branched chained alkylene group having 1 to 6 carbon atoms, and the dotted line stands for a further carbon-carbon bond or hydrogen atoms in the 3- and 4-positions of the ring, or salts thereof. The new compounds are potent diuretic agents.
    公开号:SU936809A3
    申请号:SU802942303
    申请日:1980-07-01
    公开日:1982-06-15
    发明作者:Такач Кальман；Х.Пап Мария；Ковач Габор；К.Айзерт Илона；Шимаи Антал；Литерати Надь Петер；Е.Пушкаш Мариан；Шебештиен Дьюла；Штадлер Иштван；Шюмегхи Золтан
    申请人:Хиноин Дьедьсер Еш Ведьесети Термекек Дьяра Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new sulfur-containing derivatives of isoquinoline.
    It is known that sulfur-containing derivatives of isoquinoline having a heterocyclic group as a substituent have antispasmodic and vasodilating effects of DJ.
    These derivatives can be obtained by reacting derivatives of 1-halogenomethyl-isoquinol. On and heterocyclic compounds containing a sulfohydryl group.
    The purpose of the invention is the synthesis of new 'derivatives of isoquinoline with physiological activity.
    The goal is achieved in that according to the method for producing compounds of the general formula
    ‘F
    where R, independently of one another, is hydrogen or alkoxy;
    R * is hydrogen or cyano;
    R is phenyl unsubstituted or substituted by halogen or a carboxy group, and the dotted line means an additional C - C bond or hydrogen at the 3, 4-positions of the ring, by reacting the isoquinoline derivative of the general formula
    ABOUT
    X-CH-Ηάΐ (s) in which
    R, R-ί has the above meanings, Hal means halogen, with a thiol of the general formula. R - SH in which
    R * · has the above meaning, with the allocation of the target product.
    (III)
    936809 4
    The reaction is carried out mainly in an organic solvent in the presence of a base.
    Derivatives of isoquinoline having salt-forming groups can be converted into salts by conventional methods by reaction with bases or acids.
    The resulting isoquinoline derivatives of general formula I can be isolated by known methods, for example, by filtration, evaporation of the solvent, crystallization and extraction. They can be purified by recrystallization or salification.
    The effect of the compounds of general formula I on prostaglandin biosynthesis is determined in a known manner. When tested as enzyme sources 20 using nick homogenate seed bubble sheep, and as a substrate - arachidonic acid. 0 conversion of substrate bound to an oxygen absorption judged by Ή3- 25 Menenius dissolved oxygen concentration (the oxygen concentration was determined by the Clark electrode). In the course of the experiments, the concentration of compounds of the general formula 30 I (in jhm / l), which is necessary to increase oxygen absorption by 50 and 100%, is determined.
    The diuretic effect of the compounds of general formula i is determined in rats. Urination and excretion io- 35 newly Na + and K + is determined by a known method. Anti-inflammatory effect is determined on plantar puffiness of rats. Swelling is caused by carrageenig. Braking is expressed in%.
    The cyclic effect of the compounds of general formula I, expressed in an increase in the activity of oxygenase substrate: arachidonic acid, is given in the table 45 .
    The concentration of compounds of the general formula I, which is necessary to increase the activity by 50 and 100%, is given in X / m / l. fifty
    Connection example Oxygenase activity AC 5O ° / o | as yu7o 3 100 200 55 4 70 1-40 5 40 80
    ί ' Table continuation ] Connection example Activity l oxygenase AC | AC 6 60 225 ' 8 48 96 9 95 - 12 .105 - 14 280 395 fifteen 62 124 18 69 133 22 720 1800
    According to studies performed on an isolated guinea pig trachea, these compounds have a relaxing effect. The action of the compound in accordance with example 9 is the same as theophylline, the action of the compound in accordance with example 4 when relaxing is 95-100%, 5 times higher than theophylline. At a dosage of 1 μg / ml, the effectiveness of the compound in accordance with example 4 is 5 times higher than. theophylline, however, the effectiveness of the compounds in accordance with example 9 in this case is twice lower than theophylline. The effect of the compound in accordance with example 4 appears even at a dosage of 0.1 μg / ml.
    According to their effect on the ileum of the guinea pig, the proposed compounds are antagonists in comparison with acetylcholine and histamine. At a dosage of 50 μg / ml, theophylline antagonist causes inhibition of 16% with respect to acetylcholine. The effect of the compound in accordance with example 9 is the same as theophylline, the effect of the compound in accordance with example 4 is six times higher. The maximum inhibition in the case of theophylline is 30% (at a dosage of 200 μg / ml), in the case of the compound in accordance with Example 4 it is 100% 1 at a dosage of 50 μg / ml), and the compound in accordance with Example 9 is “55% (at a dosage 100 μg / ml).
    At a dosage of 50 μg / ml, theophylline antagonist with respect to histamine ^ induces an inhibition of 18%. The action of the compound according to Example 9 is also the same as theophylline, and the compound according to Example 4 is six times higher. The maximum inhibition in the case of theophylline is 37% (at a dosage of 200 μg / ml), in the case of the compound in accordance with example 4 it is equal to .100% (at a dosage of 50 μg / ml), and in the case of the compound in accordance with example 9 “26% (at a dosage of 100 μg / ml Λ
    The effect of the proposed compounds as antagonists of serotonin is tested on the strips of the bottom of the stomach of rats. At a dosage of 10 μg / ml, theophylline antagonist causes an inhibition of 8%, the compound according to Example 9 also 8%, the compound according to Example 6-16%, and the compound according to Example 4-80%.
    Example). 0.46 g of sodium is dissolved in 50 ml of abs. ethanol and 1.54 g of thiosalicylic acid are added to the resulting sodium ethylate solution. The reaction mixture is boiled and 3.1 g of c-β-bromo-1-cyanomethyl-6,7-dimethoxy-3,4-dihydroisoquinoline dissolved in 100 ml of abs. Are added dropwise to the resulting solution. ethanol. The reaction mixture is boiled for 0.5 h, after which the solvent is distilled off in vacuo. The residue is mixed with water (with the addition of a few drops of 10% sodium hydroxide). The resulting solution was treated with activated carbon and filtered. The pH of the filtrate is adjusted with concentrated hydrochloric acid to 4. The result is 1.6 g of aL ~ (2-carboxyphenyl) -mercaptr-6.7 “Dimethoxy-3,4-dihydro-1 '• isoquinolyl-acetonitrile. Mp 245 “247 ° C (after recrystallization from a mixture of dimethylformamide and water taken in a ratio of 1: 1) 382.43.
    Calculated,%: C 62.81; H 4.74;
    N, 7.33.
    Found,%: C 63.03; H 4.85;
    N, 7.05.
    PRI me R 2. In the same way 55 as in the case of example 1, using | 1.8 g of 1-chloromethyl-isoquinoline and 1.54 g as starting compounds
    936809. 4 thiosalic acid, obtained 1.1 g of $ - (1 ~ isoquinolylmethyl) - <- mercaptobenzoic acid. Mp 1701/2 * C (after recrystallization from 5 isopropanol). Mol.weight 295.35.
    Calculated,%: S 10.86. C ^ NO ^ S
    Found,%: S 10.50. Example 3. 0.46 g of sodium paradise are dissolved in 50 ml of abs. ethanol and 1.1 g of thiophenol is added to the resulting sodium ethoxide solution. The reaction mixture is boiled and a solution of 3.1 g-bromo-1-cyanomethyl15 -6.7 ~ dimethoxy-3,4-dihydroisoquinoline is added to it. in 100 ml abs. ethanol. The reaction mixture is boiled for another 4-6 hours, after which the solvent is distilled off in vacuo. The residue was dissolved in 20 ml of 20 abs. Ethanol, treated with activated carbon and filtered. After cooling, 2.6 g of the crystalline precipitate of οί-phenylmercapto-6,7-dimethoxy-3, 4-di25 hydro, -1-isoquinolyl-acetonitrile precipitated. Mp 1bO-1b1 ° C (after recrystallization from abs. Ethanol), Mol. weight. 338.42.
    Calculated,%: C 67.43; H 5.36; Zo N 8.28; S 9.48.
    02.S Found,%: C 66.83; H 5.49; N, 8.39; S 9.39.
    PRI me R 4. In the same way, 35 as in example 3, using as starting compounds 3.4 g oC-bromo-1-cyano-methyl-6,7 “Diethoxy-3,4-dihydro-1 -isoquinoline and 1.1 g of thiophenol get 2.4 g of o £ - phenylmercapto-6,7 “ 40- diethoxy-3,4-dihydro-1-isoquinolylacetonitrile.
    Mp 118-119 ° C (after recrystallization from abs. Ethanol). Like weight. 366.47.
    45 Calculated,%: C 66.82; H 6.05;
    N, 7.65; S 8.75 (yyj z o t s
    Found,%: C 66.81; H 6.51; N, 7.34; S 8.62.
    权利要求:
    Claims (2)
    [1]
    3 The reaction is carried out predominantly in the medium of an organic solvent in the presence of a base. Isoquinoline derivatives having salt-forming groups can be converted into salts by conventional means by reaction with bases or acids. The resulting isoquinoline derivatives of the general formula I can be separated by known methods, for example by filtration, evaporation of the solvent, crystallization and extraction. They can be purified by recrystallization or salification. The effect of compounds of general formula I on prostaglandin biosynthesis is determined by a known method. When testing, a sheep seed bladder is used as a source of enzyme, and arachidonic acid is used as a substrate. The conversion of the substrate associated with the absorption of oxygen is judged by the change in the concentration of dissolved oxygen (the oxygen concentration is determined using a Clarke electrode). In the course of the experiments, the concentration of compounds of general formula I (in Jf / l) required to increase oxygen absorption by 50 and 100 is determined. The diuretic effect of compounds of general formula I is determined in rats. The urination and excretion of Na and K ions is determined in a known manner. Anti-inflammatory effects are determined on rats. Puffiness is caused by carrageenum. Inhibition is expressed in%. The cyclical action of compounds of general formula I, expressed in an increase in the activity of an oxygenase substrate: arachidonic acid, is given in the table. The concentration of compounds of general formula 1 is necessary to increase the activity by 50 and 100 is given in D / m / l. 9 According to studies performed on an isolated guinea pig trachea, these compounds have a relaxing effect. The effect of the compound in accordance with Example 9 is the same as that of theophilusation with example C when relaxing is 95-10 5 times higher than that of theophylline. At a dosage of 1 µg / ml, the effectiveness of the compound in accordance with Example 4 is 5 times higher than. theophylline, however, the effectiveness of the compound according to Example 3 in the case is twice as low as that of theophylline. The effect of the compound in accordance with Example k appears even at a dosage of 0.1 µg / ml. In terms of their effect on the guinea pigs intestine, the proposed compounds are antagonists compared with acetylcholine and histamine. At a dosage of 50 μg / ml, the theophilin antagonist causes inhibition of 6% relative to acetylcholine. The effect of the compound in accordance with example 9 is the same as that of the | | or on; the effect of the compound in accordance with example t is six times higher. The maximum inhibition in the case of theophylline is 30% (at a dosage of 200 µg / ml), in the case of a compound according to example k, it is 100 1. at a dosage of 50 µg / ml}, the compounds are in accordance with example 9-55% {at a dosage of 100 µg / ml) At a dosage of 50 µg / ml, the theophilin antagonist in relation to histamine causes inhibition 18. The effect of the compound in accordance with Example 9 is the same as that of theophylline, and the compound in accordance with Example k is six times higher. The maximum inhibition in the case of theophylline 37 (at a dosage of 200 µg / mlj, in the case of a compound in accordance with example k, it is given to LOO (at a dosage of 50 µg / ml), and in the case of a compound in accordance with example 9, 26% (at a dosage of 100 μg / mlL The effect of the proposed compounds as serotonin antagonists is tested on the ratus stomach stripes. At a dosage of 10 μg / ml, the theophilin antagonist causes inhibition 8, the compound in accordance with Example 9 also 8, the compound in accordance with Example 6-16, and the compound in according to example -80. and measure 1. 0, C6 g of sodium is dissolved in 50 ml of abs. ethanol, and 1.5 g of thiosalicylic acid is added to the resulting solution of sodium ethylate. The reaction mixture is boiled and added; to the resulting solution is added dropwise m 3.1 g o-bromo-1-cyanomethyl-6, 7 dimethoxy-3, -dihydroisoquinoline dissolved in 100 ml of absolute ethanol.The reaction mixture is boiled for 0.5 h, after which the solvent is distilled off under vacuum. The residue is mixed with water (with a few drops of 10% sodium hydroxide added). The resulting solution is treated with activated carbon and filtered. The pH of the filtrate is adjusted with concentrated hydrochloric acid to C. The result is 1.6 g (2-carboxyphenyl-mercapto-6, 7-dimethoxy-3, -dihydro-1-isoquinolyl-cetonitrile. mp. (after recrystallization from a mixture of dimethylformamide and water, taken in a 1: 1 ratio) Mol weight: 382.43. Calculated: D: 62.81; H, N, 7.33. Found, ° C: 63.03; H, 85; N 7.05. PRI mme R 2. In the same way as in the case of Example 1, using as starting compounds 1.8 1-chloromethyl-isoquinoline and 1.5 g 9. , get 1.1 g of $ - (1-isoquinolylmethyl) -2-mercaptobenzo oh acid. Tp.170l72 C (after recrystallization from isopropanol. Mol. weight 295.35. Calculated: S 10.86. 17 And ° 2.5, Found,%: $ 10.50. Frozen. About, "6 g of sodium is dissolved in 50 ml of abs. of ethanol and 1.1 g of thiophenol is added to the resulting solution of sodium ethylate and the reaction mixture is boiled and a solution of 3.1 g of o-bromo-1-cyanomethyl-6, 7 is added to it. -Dimethoxy-3, A-dihydroisoquinoline in 100 ml of absolute ethanol.The reaction mixture is boiled for another k-6 h, after which the solvent is distilled off in vacuo. The residue is dissolved in 20 ml of abs. Ethanol, treated with activated carbon and filtered. After cooling, 2.6 g of oi-phenylmercapto-6,7-dimethoxy-3, -dihydro-1-isoquinolyl-acetonitrile precipitate from the filtrate. M.p. 160-161 C (after recrystallization from abs.ethanol. Mol. Weight. 338.42. Calculated D: C 67.3; H 5.36; N 8.28; S 9.8. Q / P HYgN. Found,% : C 66.83; H 5, N 8.39; S 9.39. EXAMPLE 4 In the same manner as in Example 3, using as starting compounds, k g cL-brom-1 - cyano-methyl-6,7-diethoxy-3, t-dihydro-1-isoquinoline and 1.1 g of thiophenol, 2 g are obtained; A g o -phenylmercapto-6,7-diethoxy-3, α-dihydro-1-isoquinolyl acetonitrile. Mp 118-P9c (after recrystallization from abs. Ethanol. Mol. Weight. 366.7. Calculated,%: C 66.82; H 6.05; N 7.65; S 8.75 .fUNzOiS Found; C 66.81; H 6.51; N 7, S 8.62. 1. Invention method. containing isoquinoline derivatives of the general formula 1 g R-: n-S7 9368 in which R, independently of one another, denotes hydrogen or C coxy, hydrogen or cyano, R is unsubstituted or substituted by ha-j logene or carboxy, phenyl, and the dotted line means an additional C-C bond or hydrogen at the 3, 4-position of the ring, which is also distinguished by the fact that a reaction is carried out between the isoquinoline derivative of the general formula -rg K-CH-On (II) 9-8 in which R, R is as defined above, Hal means a halogen with a thiol of the general formula R - SH in which. R is as defined above, with isolation of the desired product.
    [2]
    2. The way pop, 1, otlimayusch; and so that the reaction is carried out in an organic solvent medium in the presence of a base. Sources of information taken into account during the examination 1. Japanese Application No. 7b325b9, “L-2is) - 16 (16).
    类似技术:
    公开号 | 公开日 | 专利标题
    US5290782A|1994-03-01|Xanthine derivatives
    SU1227110A3|1986-04-23|Method of producing 1,4-dihydropiridine derivatives or their pharmaceutically acceptable salts
    SU1436879A3|1988-11-07|Method of producing substituted nitrogen-containing bicyclic compounds or stereoisomers thereof or stereisomer mixture or acid-additive salts thereof
    US5510353A|1996-04-23|Certain aminoguanidine compounds, pharmaceutical compositions containing them and their use in treating gastrointestinal motility disorders and disorders associated with cephalic pain
    AU612437B2|1991-07-11|Tricyclic compounds
    US5068236A|1991-11-26|Xanthine derivatives
    HU223086B1|2004-03-29|Cyclic and heterocyclic n-substituted alpha-iminohydroxamic and carboxylic acids with metalloproteinase inhibitor activity, preparation and use thereof
    IL123939A|2001-11-25|Heterocyclic derivatives and pharmaceutical compositions containing the same
    EP0559893B1|1999-02-03|Xanthine derivative
    PT91351B|1997-01-31|METHOD FOR THE PREPARATION OF ALCOXY-4- | -PYRIDONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    SU936809A3|1982-06-15|Process for producing sulphur-containing derivatives of isoquinoline
    US3705907A|1972-12-12|4-|-3-aminopropoxy)-indole derivatives
    EP0122978B1|1988-05-18|Therapeutically active di-, tri-, tetra- and penta-aza indenes
    SU772484A3|1980-10-15|Method of preparing benzodiazepinone derivatives or their salts
    SU1223843A3|1986-04-07|Method of producing 1-phenyl-2-aminocarbonylindole compounds or acid-additive salts thereof
    EP0501379A2|1992-09-02|Xanthine compounds
    US4220774A|1980-09-02|Vincadifformine synthesis process
    EP0816338A1|1998-01-07|3-|oxindole derivatives
    FI70009B|1986-01-31|FRAMEWORK FOR THE FRAMEWORK OF NYA 1,5-DISUBSTITUERAD-2-PYRROLIDONFOERENINGAR VILKA HAR PROSTAGLANDINLIKNANDE BIOLOGISKA EGENSKAPER
    CS199604B2|1980-07-31|Method of producing derivatives of 4-/2-hydroxy-3-aminopropoxy/indole
    PT91117B|1995-07-06|PREPARATION PROCEDURE FOR PYRIDAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    FR2711992A1|1995-05-12|New heterocyclic derivatives, process of preparation and pharmaceutical composition containing them
    CA2091553A1|1993-09-13|Xanthine derivatives
    US4609733A|1986-09-02|3-keto-substituted-N-pyridylindoles
    EP0426573B1|1995-05-24|Phenoxypropylamine derivatives or salts thereof and antiulcer agents containing the same
    同族专利:
    公开号 | 公开日
    NL190700B|1994-02-01|
    FI76324C|1988-10-10|
    CS221811B2|1983-04-29|
    PL225380A1|1981-10-02|
    DK160422B|1991-03-11|
    YU170480A|1983-06-30|
    GB2053914B|1983-04-27|
    DD151751A5|1981-11-04|
    GR69299B|1982-05-13|
    FR2460934A1|1981-01-30|
    ES493569A0|1981-07-01|
    BG36934A3|1985-02-15|
    SU1047389A3|1983-10-07|
    JPH0131502B2|1989-06-26|
    BE884101A|1980-11-03|
    DK160422C|1991-08-19|
    NO155539B|1987-01-05|
    ATA334880A|1984-05-15|
    IN151448B|1983-04-23|
    FI802093A|1981-01-03|
    DK284880A|1981-01-03|
    PT71472A|1980-07-01|
    NO801982L|1981-01-05|
    AT376664B|1984-12-27|
    CH651554A5|1985-09-30|
    SE8004869L|1981-01-03|
    NL190700C|1994-07-01|
    AU534697B2|1984-02-09|
    FR2460934B1|1984-12-21|
    HU178454B|1982-05-28|
    IL60408A|1984-11-30|
    BG36631A3|1984-12-16|
    GB2053914A|1981-02-11|
    SE455701B|1988-08-01|
    DE3023717C2|1991-03-21|
    FI76324B|1988-06-30|
    CS221810B2|1983-04-29|
    DE3023717A1|1981-01-29|
    NO155539C|1987-04-15|
    AU6000180A|1981-02-05|
    NL8003803A|1981-01-06|
    PL230938A1|1982-03-15|
    US4373104A|1983-02-08|
    JPS5649365A|1981-05-02|
    ES8105715A1|1981-09-01|
    PL124602B1|1983-02-28|
    PL126804B1|1983-08-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2985649A|1959-09-17|1961-05-23|Pfizer & Co C|Derivatives of thiabenzopyrrocoline, thiabenzopyridocoline and thiazepine|
    GB1145254A|1965-03-18|1969-03-12|Bristol Myers Co|Novel tetrahydroisoquinoline derivatives and a process for the preparation thereof|
    GB1127525A|1966-04-01|1968-09-18|Pfizer Ltd|Di- and tetrahydroisoquinoline derivatives|
    US3389140A|1966-05-16|1968-06-18|Bristol Myers Co|1-beta-arylaminoethyl-2-methyl-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinolines|
    US3389141A|1966-05-16|1968-06-18|Bristol Myers Co|1-beta-aryloxyethyltetrahydro-isoquinolines|
    US3455933A|1966-11-15|1969-07-15|American Home Prod|Thiazolo and thiazino isoquinoline derivatives|
    FR2119989B1|1970-12-29|1975-10-10|Fujisawa Pharmaceutical Co|
    JPS5516138B2|1971-11-17|1980-04-30|
    AT333763B|1972-06-20|1976-12-10|Fujisawa Pharmaceutical Co|PROCESS FOR THE PREPARATION OF NEW 1,2,3,4-TETRAHYDROISOCHINOLINES AND THEIR SALTS|
    HU170680B|1973-05-30|1977-08-28|
    AT351540B|1974-07-17|1979-07-25|Fujisawa Pharmaceutical Co|PROCESS FOR THE PREPARATION OF NEW TETRAHYDROISOCHINOLINE DERIVATIVES AND THEIR SALTS|
    AT538789T|2006-10-06|2012-01-15|Toyama Chemical Co Ltd|PHARMACEUTICAL COMPOSITION WITH A PHENYLAMIDINE DERIVATIVE AND METHOD FOR THE USE OF THE PHARMACEUTICAL COMPOSITION COMBINED WITH AN ANTIMYCOTIC AGENT|
    CN101616959A|2007-02-20|2009-12-30|三井化学株式会社|Thietane compound, the Polymerizable composition that contains it and application thereof|
    JP5180867B2|2009-02-13|2013-04-10|信越ポリマー株式会社|Substrate storage container|
    JP5186477B2|2009-12-28|2013-04-17|株式会社ホンダエレシス|Occupant detection device|SE8300736D0|1983-02-11|1983-02-11|Haessle Ab|NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS|
    HU189764B|1983-10-25|1986-07-28|Richter Gedeon Vegyeszeti Gyar Rt,Hu|Process for preparing 1--methyl)-isoquinoline-derivatives|
    HU189765B|1983-10-25|1986-07-28|Richter Gedeon Vegyeszeti Gyar Rt,Hu|Process for preparing n-substituted 1--methyl)-isoquinoline-derivatives|
    US4584379A|1985-01-22|1986-04-22|Merrell Dow Pharmaceuticals Inc.|Isoquinoline thromboxane synthetase inhibitors|
    JPS63236994A|1987-03-26|1988-10-03|Sankyo Seiki Seisakusho Kk|Shielding member|
    HU209930B|1990-11-14|1994-12-28|Chinoin Gyogyszer Es Vegyeszet|Process for producing of 2-mercapto-2--acetonitrile derivatives and pharmaceutical compositions comprising them|
    DE4343683A1|1993-12-21|1995-06-22|Boehringer Ingelheim Kg|Anellated dihydropyridines and their use for the preparation of pharmaceutical preparations|
    HU0000920A3|2000-02-28|2002-03-28|Sanofi Synthelabo|Pde4 inhibitor isoquinolinylidene derivatives, process for their preparation and medicaments containing them|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU79CI1944A|HU178454B|1979-07-02|1979-07-02|Process for preparing new isoquinoline derivatives containing sulphur|
    [返回顶部]